Tesamorelin

What it is (in plain language)
- It is the most powerful peptide for attacking belly fat. Unlike other secretagogues, Tesamorelin was designed to be very stable and effective in reducing visceral fat (the kind that sits between the organs). It increases IGF-1 but focuses intensely on abdominal recomposition.

Why do you appear online so much
- It is the 'secret' of many elite fitness protocols for achieving extreme abdominal definition. It is also one of the few peptides in this class with strict FDA approval for specific fat loss purposes.

How it is framed today (pragmatic view)
- 1) Evidence: Approved (Egrifta) with robust human studies. 2) Objective: Reduction of visceral fat and improvement of lipid profile. 3) Risk: May slightly affect glucose tolerance; requires blood sugar monitoring.

How to use this form
- Analyse the 'Metabolism' section to understand why this compound is superior to standard GH for visceral fat loss.

- Quick profile (curated by Subject 157)
- Class: Hormonal
- Status: Verified
- Use case: Hormonal
- Route: Injectable
- Tags: Injectable|Fat Loss|Approved
- Half-life: ~30 Mins
- Start: Fast
- Duration: Variable

- Mechanism (high level)
Stabilised analogue of GHRH. Stimulates GH secretion in a powerful and sustained way, with specific effects on reducing visceral adipose tissue (VAT).

- Evidence (what the literature covers)
RESEARCH RANGE (Clinical, Non-prescriptive):
Clinical doses of 1mg to 2mg daily.
Level of Evidence: A (FDA Approved - Egrifta).

- Safety and harm-reduction (non-prescriptive)
Risks: Injection site reactions, joint pain, risk of diabetes (IGF-1).
Interactions: Unknown.

- References (anchors)
- Stanley, T. L. (2010) - Tesamorelin reduces visceral fat in HIV - https://doi.org/10.1097/QAI.0b013e3181cbdaff | PubMed:20305481
- Stanley, T. (2014) - Tesamorelin effects on visceral and liver fat - https://doi.org/10.1001/jama.2014.8334 | PubMed:25058721

Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.